The integrase strand transfer inhibitor dolutegravir (DTG) has a high genetic barrier to resistance. Only rare cases of resistance to DTG have been reported when it is used as a component of antiretroviral therapy regimens in treatment-experienced patients unless there was prior use of a first-generation integrase inhibitor.

中文翻译：

---

病例报告：一名接受二线抗逆转录病毒治疗的患者出现多替拉韦耐药。

整合酶链转移抑制剂 dolutegravir (DTG) 具有很高的抗性遗传屏障。除非先前使用过第一代整合酶抑制剂，否则仅报告了将 DTG 作为抗逆转录病毒治疗方案的组成部分用于接受过治疗的患者时对 DTG 产生耐药性的罕见病例。